Zoetis Inc. (NYSE:ZTS) Stock Position Decreased by D.A. Davidson & CO.

D.A. Davidson & CO. cut its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,095 shares of the company's stock after selling 1,585 shares during the quarter. D.A. Davidson & CO.'s holdings in Zoetis were worth $3,803,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZTS. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in shares of Zoetis by 5.4% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock worth $68,354,000 after acquiring an additional 21,470 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Zoetis by 61.0% during the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock worth $497,000 after acquiring an additional 1,157 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Zoetis during the 4th quarter worth $196,651,000. Finally, E Fund Management Co. Ltd. boosted its position in shares of Zoetis by 80.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 2,946 shares of the company's stock worth $480,000 after buying an additional 1,315 shares during the period. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the company. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $212.13.

Zoetis Price Performance

ZTS opened at $159.19 on Friday. The stock has a market cap of $70.87 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 2.64 and a beta of 0.91. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The stock has a fifty day moving average price of $161.16 and a 200 day moving average price of $162.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 earnings per share. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.26%. Zoetis's dividend payout ratio is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.